MedTrace Logo

Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects

NCT01733186 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.

Conditions

  • Degeneration Articular Cartilage Knee

Interventions

BIOLOGICAL

CARTISTEM®

Sponsors & Collaborators

  • Medipost, Inc.

    lead INDUSTRY

Principal Investigators

  • Brian J Cole, MD · Cartilage Restoration Center, Rush University Medical Center

  • Andreas H Gomoll, MD · Cartilage Repair Center, Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-07
Primary Completion
2017-06-02
Completion
2017-08-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01733186 on ClinicalTrials.gov